Molecular Formula | C25H31ClN2O4 |
Molar Mass | 458.97764 |
Solubility | DMSO : 250 mg/mL (544.69 mM; Need ultrasonic)H2O : 50 mg/mL (108.94 mM; ultrasonic and warming and heat to 60°C) |
Storage Condition | -20℃ |
Reference Show more | 1. Dimitrios C Mastellos, et al. Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Semin Hematol. 2018 Jul;55(3):167-175.2. Anna Schubart, et al. Small-molecule Factor B Inhibitor for the Treatment of Complement-Mediated Diseases. Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7926-7931.3. Nello Mainolfi, et al. Discovery of 4-((2 S,4 S)-4-Ethoxy-1-((5-methoxy-7-methyl-1 H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases. J Med Chem. 2020 Jun 11;63(11):5697-5722. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.179 ml | 10.894 ml | 21.787 ml |
5 mM | 0.436 ml | 2.179 ml | 4.357 ml |
10 mM | 0.218 ml | 1.089 ml | 2.179 ml |
5 mM | 0.044 ml | 0.218 ml | 0.436 ml |